Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 4/20 | 0.36 |
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700744 | 0.95 | PTGDR2 (0.33) | COMTHTR6PTGDR2KDM4EKMT2A | |
| SCHEMBL476415 | 0.89 | HTR6 (0.35) | COMTHTR6KMT2A | |
| SCHEMBL3697999 | 0.88 | P2RX7 (0.33) | PTGDR2KDM4E | |
| SCHEMBL476339 | 0.88 | HTR6 (0.32) | HTR6 | |
| SCHEMBL3705969 | 0.87 | SLC16A3 (0.39) | PTGDR2 | |
| SCHEMBL476388 | 0.86 | PKM (0.38) | COMTHTR6PTGDR2PKMKCNA5 | |
| SCHEMBL476395 | 0.86 | NAMPT (0.33) | KCNA5 | |
| SCHEMBL3699028 | 0.84 | PTGDR2 (0.34) | HTR6PTGDR2PTGDRPTGER2MAPT | |
| SCHEMBL3697762 | 0.83 | KDM4E (0.33) | PTGDR2PKMKDM4E | |
| SCHEMBL3698418 | 0.82 | PTGDR2 (0.32) | PTGDR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095057-A1 | PYRAZOLE COMPOUND | CEL, HRH2, GIPR | COMT 4484/4885HTR6 2380/4885PTGDR2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.